Privia Health Group (NASDAQ:PRVA) Shares Gap Down – Time to Sell?

Privia Health Group, Inc. (NASDAQ:PRVA) gapped down before the market opened on Thursday . The stock had previously closed at $23.96, but opened at $20.90. Privia Health Group shares last traded at $20.9930, with a volume of 401,384 shares traded.

Privia Health Group News Roundup

Here are the key news stories impacting Privia Health Group this week:

• Positive Sentiment: Revenue exceeded expectations: Second-quarter revenue rose 21.4% year over year to $632.6 million, above the $597.3 million FactSet consensus. Six-month revenue reached $1.24 billion, up 23.5%. Privia Health second-quarter revenue results
• Positive Sentiment: Profitability and operating metrics improved: Net income attributable to Privia rose to $9.0 million from $2.7 million, while adjusted EBITDA increased 29.1% to $37.4 million. Implemented providers grew 10.1% to 5,644 and value-based-care attributed lives rose 19.2% to 1.647 million. Privia Health reports second-quarter results
• Positive Sentiment: Full-year outlook was raised: Management lifted 2026 guidance for attributed lives, practice collections, care margin, platform contribution and adjusted EBITDA. GAAP revenue is now expected at $2.35 billion to $2.45 billion, with the range’s upper end viewed favorably relative to the FactSet consensus of $2.42 billion. Privia Health 2026 revenue guidance
• Neutral Sentiment: EPS interpretation was mixed: Adjusted diluted EPS of $0.19 beat the $0.07 consensus cited by some outlets, but GAAP diluted EPS was $0.07 versus a Zacks estimate of $0.08. The quarter also included $19.4 million of non-cash stock compensation, limiting the quality of reported earnings. Privia Health earnings estimate report
• Negative Sentiment: Cash generation raised concerns: Privia used $48.4 million in operating cash during the first half, driven largely by a $172.4 million increase in accounts receivable. The company also reported continued insider selling, with no insider purchases among 31 reported transactions over six months.

Analysts Set New Price Targets

PRVA has been the topic of several analyst reports. Citigroup reaffirmed a “buy” rating on shares of Privia Health Group in a report on Thursday, July 23rd. Evercore set a $26.00 target price on Privia Health Group in a research report on Wednesday, April 8th. Weiss Ratings raised Privia Health Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, July 2nd. Barclays cut their price objective on shares of Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 26th. Finally, Zacks Research cut shares of Privia Health Group from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 7th. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $31.15.

Privia Health Group Price Performance

The company has a market capitalization of $2.66 billion, a PE ratio of 131.77, a price-to-earnings-growth ratio of 1.88 and a beta of 0.85. The firm’s fifty day simple moving average is $24.61 and its 200 day simple moving average is $23.36.

Privia Health Group (NASDAQ:PRVA) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.12. The company had revenue of $632.63 million during the quarter, compared to analysts’ expectations of $597.33 million. Privia Health Group had a return on equity of 2.81% and a net margin of 0.97%.Privia Health Group’s quarterly revenue was up 21.4% on a year-over-year basis. During the same period last year, the business earned $0.24 earnings per share. On average, equities research analysts anticipate that Privia Health Group, Inc. will post 0.27 EPS for the current fiscal year.

Insider Buying and Selling at Privia Health Group

In related news, Director Matthew Shawn Morris sold 88,110 shares of the company’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $25.33, for a total value of $2,231,826.30. Following the completion of the transaction, the director owned 76,651 shares of the company’s stock, valued at approximately $1,941,569.83. This represents a 53.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Parth Mehrotra sold 105,439 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $22.55, for a total value of $2,377,649.45. Following the transaction, the chief executive officer owned 450,004 shares in the company, valued at $10,147,590.20. This represents a 18.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 452,357 shares of company stock valued at $11,436,655. Corporate insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Renaissance Group LLC purchased a new position in Privia Health Group during the fourth quarter valued at $7,776,000. Principal Financial Group Inc. raised its position in shares of Privia Health Group by 1.6% during the 4th quarter. Principal Financial Group Inc. now owns 2,787,802 shares of the company’s stock worth $66,099,000 after purchasing an additional 43,589 shares during the last quarter. Louisiana State Employees Retirement System purchased a new position in Privia Health Group in the 1st quarter valued at about $1,055,000. Van Berkom & Associates Inc. increased its stake in Privia Health Group by 5.4% during the 1st quarter. Van Berkom & Associates Inc. now owns 4,053,043 shares of the company’s stock worth $83,371,000 after buying an additional 208,787 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Privia Health Group by 6.3% during the first quarter. Dimensional Fund Advisors LP now owns 2,406,717 shares of the company’s stock valued at $49,500,000 after acquiring an additional 142,679 shares during the last quarter. Hedge funds and other institutional investors own 94.48% of the company’s stock.

About Privia Health Group

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.